Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT) a prospective, open-label, randomized study

David E. Griffith, Gina Eagle, Rachel Thomson, Timothy R. Aksamit, Naoki Hasegawa, Kozo Morimoto, Doreen J. Addrizzo-Harris, Anne E. O'Donnell, Theodore K. Marras, Patrick A. Flume, Michael R. Loebinger, Lucy Morgan, Luigi R. Codecasa, Adam T. Hill, Stephen J. Ruoss, Jae Joon Yim, Felix C. Ringshausen, Stephen K. Field, Julie V. Philley, Richard J. WallaceJakko Van Ingen, Chris Coulter, James Nezamis, Kevin L. Winthrop

研究成果: Article査読

154 被引用数 (Scopus)

フィンガープリント

「Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT) a prospective, open-label, randomized study」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

Medicine & Life Sciences